{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:22Z","timestamp":1792783102660,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bionorica SE, Germany"},{"name":"University of Bern","id":[{"id":"https:\/\/ror.org\/02k7v4d05","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To evaluate clinical characteristics, quality of life (QoL) and effectiveness in patients with menstrual cycle disorders (MCDs) including abnormal uterine bleeding, dysmenorrhea and mastodynia\/mastalgia related to premenstrual syndrome taking the\n                      <jats:italic>Vitex agnus-castus<\/jats:italic>\n                      (VAC) products Cyclodynon\u00ae or Mastodynon\u00ae in a real-world setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center retrospective longitudinal cohort study (3\u2009\u00b1\u20091\u00a0months), using data obtained from healthcare data archive and telephone interviews. The main study variables were changes in bleeding, menstrual pain, breast tenderness and patients\u2019 QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 1700 women with a mean age of 30.2\u00a0years (\u00b1\u20096.3) were analyzed. The most common MCDs were dysmenorrhea (43.8%) and mastodynia\/mastalgia (21.1%). Three-month treatment with VAC extract substantially decreased the percentage of patients with irregular cycle (from 9.1% to 0.1%) and breast tenderness (from 39.9% to 0.8%). Improvement in bleeding intensity, frequency and menstrual pain was experienced by 83.4%, 79.2%, and 85.2% of the patients, respectively. When analyzed by disease category, these parameters improved in almost all dysmenorrhea patients, while they improved to a lesser extent in mastodynia\/mastalgia patients. QoL improved in all aspects, but was reported by a higher proportion of dysmenorrhea patients compared to mastodynia\/mastalgia patients. Treatment was overall well tolerated with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These real-world data demonstrate the effectiveness of the VAC-containing products Cyclodynon\u00ae and Mastodynon\u00ae in the three-month treatment of MCDs, with a pronounced improvement in key disease symptoms and QoL. Intriguingly, while QoL was generally greatly improved, the response to VAC therapy varied depending on the type of underlying MCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-023-07363-4","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:03:07Z","timestamp":1708646587000},"page":"2089-2098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study"],"prefix":"10.1007","volume":"309","author":[{"given":"Martina","family":"H\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Steindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Abramov-Sommariva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kleemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Loleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Abels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-1552","authenticated-orcid":false,"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"7363_CR1","first-page":"40","volume":"19","author":"UC Igbokwe","year":"2021","unstructured":"Igbokwe UC, John-Akinola YO (2021) Knowledge of menstrual disorders and health seeking behaviour among female undergraduate students of University of Ibadan, Nigeria. Ann Ib Postgrad Med 19:40\u201348","journal-title":"Ann Ib Postgrad Med"},{"key":"7363_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0031-1287662","volume":"29","author":"IS Fraser","year":"2011","unstructured":"Fraser IS, Critchley HO, Broder M, Munro MG (2011) The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 29:383\u2013390","journal-title":"Semin Reprod Med"},{"key":"7363_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4939-0659-8_7","volume":"1154","author":"RL Barbieri","year":"2014","unstructured":"Barbieri RL (2014) The endocrinology of the menstrual cycle. Methods Mol Biol 1154:145\u2013169","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"7363_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/09513590.2012.651929","volume":"28","author":"S Berga","year":"2012","unstructured":"Berga S, Naftolin F (2012) Neuroendocrine control of ovulation. Gynecol Endocrinol 28(Suppl 1):9\u201313","journal-title":"Gynecol Endocrinol"},{"key":"7363_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/humupd\/dmv039","volume":"21","author":"S Iacovides","year":"2015","unstructured":"Iacovides S, Avidon I, Baker FC (2015) What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update 21:762\u2013778","journal-title":"Hum Reprod Update"},{"key":"7363_CR6","doi-asserted-by":"crossref","unstructured":"Bernardi M, Lazzeri L, Perelli F, Reis FM, Petraglia F (2017) Dysmenorrhea and related disorders. F1000Res 6:1645","DOI":"10.12688\/f1000research.11682.1"},{"key":"7363_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jpag.2010.02.009","volume":"23","author":"G Eryilmaz","year":"2010","unstructured":"Eryilmaz G, Ozdemir F, Pasinlioglu T (2010) Dysmenorrhea prevalence among adolescents in eastern Turkey: its effects on school performance and relationships with family and friends. J Pediatr Adolesc Gynecol 23:267\u2013272","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"7363_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/01.AOG.0000230214.26638.0c","volume":"108","author":"MY Dawood","year":"2006","unstructured":"Dawood MY (2006) Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 108:428\u2013441","journal-title":"Obstet Gynecol"},{"key":"7363_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00737-016-0631-7","volume":"19","author":"E Ismaili","year":"2016","unstructured":"Ismaili E, Walsh S, O\u2019Brien PMS, B\u00e4ckstr\u00f6m T, Brown C, Dennerstein L, Eriksson E, Freeman EW, Ismail KMK, Panay N, Pearlstein T, Rapkin A, Steiner M, Studd J, Sundstr\u00f6m-Paromma I, Endicott J, Epperson CN, Halbreich U, Reid R, Rubinow D, Schmidt P, Yonkers K (2016) Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health 19:953\u2013958","journal-title":"Arch Womens Ment Health"},{"key":"7363_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00737-022-01261-5","volume":"25","author":"L Hantsoo","year":"2022","unstructured":"Hantsoo L, Rangaswamy S, Voegtline K, Salimgaraev R, Zhaunova L, Payne JL (2022) Premenstrual symptoms across the lifespan in an international sample: data from a mobile application. Arch Womens Ment Health 25:903\u2013910","journal-title":"Arch Womens Ment Health"},{"issue":"3","key":"7363_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.apjtb.2015.12.008","volume":"6","author":"F Shobeiri","year":"2016","unstructured":"Shobeiri F, Oshvandi K, Nazari M (2016) Cyclical mastalgia: prevalence and associated determinants in Hamadan City, Iran. Asian Pac J Trop Biomed 6(3):275\u2013278","journal-title":"Asian Pac J Trop Biomed"},{"key":"7363_CR12","doi-asserted-by":"publisher","first-page":"1269781","DOI":"10.3389\/fendo.2023.1269781","volume":"14","author":"LT Puglia","year":"2023","unstructured":"Puglia LT, Lowry J, Tamagno G (2023) Vitex agnus castus effects on hyperprolactinaemia. Front Endocrinol (Lausanne) 14:1269781","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7363_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1078\/094471103322004866","volume":"10","author":"W Wuttke","year":"2003","unstructured":"Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlov\u00e1-Wuttke D (2003) Chaste tree (Vitex agnus-castus)\u2013pharmacology and clinical indications. Phytomedicine 10:348\u2013357","journal-title":"Phytomedicine"},{"issue":"2","key":"7363_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.33029\/1816-2134-2021-17-2-51-64","volume":"17","author":"E Uvarova","year":"2021","unstructured":"Uvarova E (2021) Effectiveness and safety of herbal medicinal product Cyclodinon in treatment of menstrual irregularities in adolescent girls: a review of clinical usage [in Russian]. Pediatr Adolesc Reprod Health 17(2):51\u201364","journal-title":"Pediatr Adolesc Reprod Health"},{"key":"7363_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bcp.2010.09.013","volume":"81","author":"DE Webster","year":"2011","unstructured":"Webster DE, He Y, Chen SN, Pauli GF, Farnsworth NR, Wang ZJ (2011) Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol 81:170\u2013177","journal-title":"Biochem Pharmacol"},{"key":"7363_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/00002018-200528040-00004","volume":"28","author":"C Daniele","year":"2005","unstructured":"Daniele C, Thompson Coon J, Pittler MH, Ernst E (2005) Vitex agnus castus: a systematic review of adverse events. Drug Saf 28:319\u2013332","journal-title":"Drug Saf"},{"key":"7363_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1055\/s-0029-1211317","volume":"102","author":"H Jarry","year":"1994","unstructured":"Jarry H, Leonhardt S, Gorkow C, Wuttke W (1994) In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 102:448\u2013454","journal-title":"Exp Clin Endocrinol"},{"key":"7363_CR18","unstructured":"European Medicines Agency (2018) Assessment report on Vitex agnus-castus L., fructus EMA\/HMPC\/606741\/2018. https:\/\/www.ema.europa.eu\/en\/documents\/herbal-report\/final-assessment-report-vitex-agnus-castus-l-fructus-revision-1_en.pdf"},{"key":"7363_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.maturitas.2006.06.014","volume":"55S","author":"H Jarry","year":"2006","unstructured":"Jarry H, Spengler B, Wuttke W, Christoffel V (2006) In vitro assays for bioactivity-guided isolation of endocrine active compounds in Vitex agnus-castus. Maturitas 55S:26\u201336","journal-title":"Maturitas"},{"key":"7363_CR20","first-page":"51","volume":"7","author":"R Mergner","year":"1992","unstructured":"Mergner R (1992) Zyklusst\u00f6rungen: Therapie mit einem Vitex agnuscastus haltigen Kombinationsarzneimitte [in German]. Der Kassenarzt 7:51\u201360","journal-title":"Der Kassenarzt"},{"key":"7363_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/jog.12221","volume":"40","author":"AN Aksoy","year":"2014","unstructured":"Aksoy AN, G\u00f6z\u00fckara I, Kabil Kucur S (2014) Evaluation of the efficacy of Fructus agni casti in women with severe primary dysmenorrhea: a prospective comparative Doppler study. J Obstet Gynaecol Res 40:779\u2013784","journal-title":"J Obstet Gynaecol Res"},{"key":"7363_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00737-017-0791-0","volume":"20","author":"RO Cerqueira","year":"2017","unstructured":"Cerqueira RO, Frey BN, Leclerc E, Brietzke E (2017) Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health 20:713\u2013719","journal-title":"Arch Womens Ment Health"},{"key":"7363_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13760-012-0111-4","volume":"113","author":"A Ambrosini","year":"2013","unstructured":"Ambrosini A, Di Lorenzo C, Coppola G, Pierelli F (2013) Use of Vitex agnus-castus in migrainous women with premenstrual syndrome: an open-label clinical observation. Acta Neurol Belg 113:25\u201329","journal-title":"Acta Neurol Belg"},{"key":"7363_CR24","first-page":"118","volume":"7","author":"S Zhuk","year":"2014","unstructured":"Zhuk S, Nochvina O (2014) New approaches to the treatment of primary dysmenorrhea in aspects of psychosomatic disorders [in Ukrainian]. Health of Woman 7:118\u2013122","journal-title":"Health of Woman"},{"key":"7363_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/bmj.319.7211.652","volume":"319","author":"B Haynes","year":"1999","unstructured":"Haynes B (1999) Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 319:652\u2013653","journal-title":"BMJ"},{"key":"7363_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/jwh.2019.7770","volume":"29","author":"SL Ooi","year":"2020","unstructured":"Ooi SL, Watts S, McClean R, Pak SC (2020) Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis. J Womens Health (Larchmt) 29:262\u2013278","journal-title":"J Womens Health (Larchmt)"},{"key":"7363_CR27","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.19082\/3685","volume":"9","author":"M Rafieian-Kopaei","year":"2017","unstructured":"Rafieian-Kopaei M, Movahedi M (2017) Systematic review of premenstrual, postmenstrual and infertility disorders of Vitex agnus castus. Electron Physician 9:3685\u20133689","journal-title":"Electron Physician"},{"key":"7363_CR28","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.12998\/wjcc.v8.i15.3259","volume":"8","author":"L Wang","year":"2020","unstructured":"Wang L, Guan HY, Xia HX, Chen XY, Zhang W (2020) Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding\u2014ovulation dysfunction patients. World J Clin Cases 8:3259\u20133266","journal-title":"World J Clin Cases"},{"key":"7363_CR29","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1093\/humrep\/der224","volume":"26","author":"IS Fraser","year":"2011","unstructured":"Fraser IS, Romer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT (2011) Effective treatment of heavy and\/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind phase III trial. Hum Reprod 26:2698\u20132708","journal-title":"Hum Reprod"},{"key":"7363_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0002-9378(99)70142-0","volume":"180","author":"PM O\u2019Brien","year":"1999","unstructured":"O\u2019Brien PM, Abukhalil IE (1999) Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 180:18\u201323","journal-title":"Am J Obstet Gynecol"},{"key":"7363_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0028-2243(92)90177-Z","volume":"43","author":"S Uzan","year":"1992","unstructured":"Uzan S, Denis C, Pomi V, Varin C (1992) Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol 43:219\u2013227","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"7363_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijgo.2004.01.001","volume":"85","author":"EB Kilicdag","year":"2004","unstructured":"Kilicdag EB, Tarim E, Bagis T, Erkanli S, Aslan E, Ozsahin K, Kuscu E (2004) Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet 85:292\u2013293","journal-title":"Int J Gynaecol Obstet"},{"key":"7363_CR33","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s11136-017-1562-0","volume":"26","author":"AM Nguyen","year":"2017","unstructured":"Nguyen AM, Arbuckle R, Korver T, Chen F, Taylor B, Turnbull A, Norquist JM (2017) Psychometric validation of the dysmenorrhea daily diary (DysDD): a patient-reported outcome for dysmenorrhea. Qual Life Res 26:2041\u20132055","journal-title":"Qual Life Res"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-07363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-023-07363-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-07363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T01:07:07Z","timestamp":1713143227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-023-07363-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["7363"],"URL":"https:\/\/doi.org\/10.1007\/s00404-023-07363-4","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value and rigor and follow generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE), Good Epidemiological Practice (GEP) guidelines issued by the International Epidemiological Association (IEA), Good Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), International Ethical Guidelines for Epidemiological Research issued by the Council for International Organizations of Medical Sciences (CIOMS).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martina H\u00f6ller, Hubert Steindl, Dimitri Abramov-Sommariva, Julia Kleemann and Christoph Abels are employees of Bionorica SE; Alexey Loleit is an employee of Traverse Health Europe B.V. and was an employee of Data Matrix GmbH during the conduct of the study. Petra Stute has received honoraria as a speaker at conferences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Independent Ethics Committee PharmNadzor LLC, Saint Petersburg, Russia on May 26th 2022 (document number: Extract#7 from the minutes of the meeting #324).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Verbal informed consent was obtained prior to the QoL interview. No informed consent was required for other data collected due to the retrospective nature of the study with fully anonymized data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}